Positioning political selling, disclosed 2026-09-11
Options put/call open interest 0.90, read 2026-11-05
Ethical passes the values gate
Price44.64 USD
Fair value60.24
Ethical score86.9/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-24Read Markup44.14+1.1% to today ✓Markdown gives way to Markup first Markup read since August
2026-10-23Read Markdown44.14+1.1% to today Accumulation gives way to Markdown with results news in the headlines
2026-10-18Read Accumulation44.14+1.1% to today ✓Distribution gives way to Accumulation
2026-10-02Read Distribution43.92+1.6% to today Markup gives way to Distribution after an 11% slide in 5 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Boston Scientific holds its Markup at $44.64. The statistical read favours the buyers, held for 2 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 2 days
Price at the screen
$44.64
Valuation
18.01 trailing · 13.33 forward price to earnings
Values screen
PASS· score 86.9
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
26.19%
Below 33%
Interest-bearing debt is just 26.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
11.20%
Below 49%
Money owed to the company is 11.2% of assets, under the 49% limit.
Pass
Revenue purity
0.14%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Boston Scientific clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 26%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BSX's ethical verdict changes
Today BSX passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 26% discount to our $60.24 fair value, moderate competitive moat, 1.40% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 25.9% discount to the base estimate.
Where our models see it going: fair-value estimate $60.24, with a range of $52.86 to $88.10, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
The quiet tools fixing hearts in operating rooms
When a cardiologist threads a stent through a blocked artery in Boston or Berlin, Boston Scientific makes the device that gets the job done. The firm builds tools for heart and digestive procedures in two focused divisions. It stands out because revenue climbs 12 percent a year, margins sit at 17 percent, and the shares trade at just 11.9 times forward earnings against a fair value that implies 72 percent upside.
Return on equity reaches 15 percent with a moderate moat and a clean ethical pass. Twenty-eight analysts carry a strong buy rating with a 70 dollar median target. The business grows steadily in a defensive sector where demand rarely vanishes.
Regulation, hospital budget cuts and rival devices remain real threats that could test pricing power. Currency swings add another layer in markets outside the United States. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BSX trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup$43.50-1.4%Entry 23
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83.
2026-10-28Markup$44.14+0.0%Entry 22
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$44.14+0.0%Entry 21
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup$44.14+0.0%Entry 20
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$44.14+0.0%Entry 19
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markup · changed$44.14+0.0%Entry 18
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown · changed$44.14+0.0%Entry 17
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$44.14+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$44.14+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 52%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (32 analysts) rates it strong buy, with a mean price target of $83.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
